EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual‐Enhanced SERS Satellite Immuno‐Nanocomplex for Multiple PSA‐Mediated PHI Assay Toward Clinical Prostate Cancer Screening

Dong Chen, Yilin Ma, Annan Yang, Liping Hu, Hanlin Zhou, Jun Xu, Shanze Chen, Dingmeng Nie, Weifeng Feng, Huaihong Cai, Yanguang Cong, Jiang Pi und 4 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202411747 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Dong Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Safflower Industry Research, Key Laboratory of Xinjiang Phytomedicine Resource and Utilization (Ministry of Education), School of Pharm…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Spectrum Analysis, Raman, Early Detection of Cancer. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate specific antigen (PSA) is widely used in liquid biopsy of prostate cancer (PCa) but still faces challenges due to the poor specificity. Herein, this study reports a double‐SERS satellite immunoassay, made of an Au–Ag dealloyed intra‐nanogap nanoflower (Au–Ag DINF) with strong SERS signals and Au magnetic nanoparticles (AuMNPs) with magnetic capture and SERS amplification, for sensing multiple PSA (free PSA (fPSA), complexed PSA (cPSA) and [‐2]proPSA (p2PSA)) toward potential PCa screening. Unlike the previous studies focus on the tPSA and fPSA/tPSA ratio (f/t PSA%), this work introduces a multiple PSA‐mediated Prostate Health Index (PHI) assay with significantly increased the predictive accuracy and specificity of PCa, especially the patients with a tPSA level in the “diagnostic gray zone”. Practical analysis of clinical samples demonstrated the SERS immunoassay is capable of identifying the PCa subjects from healthy candidates ( N = 13), and monitoring PCa patients before and after surgery ( N = 5), as well as screening suspicious ones who are in the “gray zone” ( N = 10). Overall, benefiting from the PSA‐responsive satellite immuno‐nanoassemble strategy, dual‐SERS magnification effect, and multiple PSA‐based PHI assessment, this proposes bioassay held enormous potential for the early diagnosis, screening, monitoring, and prognosis of PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenSpectrum Analysis, RamanEarly Detection of CancerMaleHumansImmunoassayGoldMetal Nanoparticles

Stichwörter der Autor:innen

PCa screeningintra‐nanogap particlesprostate health indexprostate specific antigensurface‐enhanced raman scattering

Substanzen

Prostate-Specific AntigenGold

Autor:innen und Institutionen

  • Institute for Safflower Industry Research, Key Laboratory of Xinjiang Phytomedicine Resource and Utilization (Ministry of Education), School of Pharmacy, Shihezi University, Shihezi, 832003, China.
  • Department of Urology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • College of Pharmacy, The Second Clinical Medical College (Shenzhen People's Hospital), The Fifth Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
  • Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518132, China.
  • The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
  • College of Chemistry and Materials Science, Jinan University, Guangzhou, 510632, China.

ORCID-Profile: Lang Rao

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Science and Technology Projects in Guangzhou
  • Xinjiang Safflower Industry Development Fund

Zitieren

APA

Chen, D., Ma, Y., Yang, A., Hu, L., Zhou, H., Xu, J., Chen, S., Nie, D., Feng, W., Cai, H., Cong, Y., Pi, J., Rao, L., Huang, X., Sun, P., & Zhou, H. (2025). Dual‐Enhanced SERS Satellite Immuno‐Nanocomplex for Multiple PSA‐Mediated PHI Assay Toward Clinical Prostate Cancer Screening. Advanced Science. https://doi.org/10.1002/advs.202411747

Vancouver

Chen D, Ma Y, Yang A, Hu L, Zhou H, Xu J, et al. Dual‐Enhanced SERS Satellite Immuno‐Nanocomplex for Multiple PSA‐Mediated PHI Assay Toward Clinical Prostate Cancer Screening. Advanced Science. 2025. doi:10.1002/advs.202411747

BibTeX
@article{Chen2025,
  author = {Chen, Dong and Ma, Yilin and Yang, Annan and Hu, Liping and Zhou, Hanlin and Xu, Jun and Chen, Shanze and Nie, Dingmeng and Feng, Weifeng and Cai, Huaihong and Cong, Yanguang and Pi, Jiang and Rao, Lang and Huang, Xueqin and Sun, Pinghua and Zhou, Haibo},
  title = {Dual‐Enhanced SERS Satellite Immuno‐Nanocomplex for Multiple PSA‐Mediated PHI Assay Toward Clinical Prostate Cancer Screening},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202411747}
}
Kostenlos starten →